• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PTPRD 突变是晚期非小细胞肺癌对免疫检查点抑制剂治疗敏感性的预后生物标志物。

PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer.

机构信息

Department of Radiation Oncology, Huadong Hospital, Fudan University, Shanghai 200433, P.R. China.

Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, P.R. China.

出版信息

Aging (Albany NY). 2023 Aug 18;15(16):8204-8219. doi: 10.18632/aging.204964.

DOI:10.18632/aging.204964
PMID:37602864
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10497019/
Abstract

BACKGROUND

Immune checkpoint inhibitors (ICIs) have become the standard treatment for advanced non-small cell lung cancer (NSCLC). ICIs can provide durable responses and prolong survival for some patients. With the increasing routine of next-generation sequencing (NGS) in clinical practice, it is essential to integrate prognostic factors to establish novel nomograms to improve clinical prediction ability in NSCLC with ICIs treatment.

METHODS

Clinical information, response data, and genome data of advanced NSCLC treated ICIs were obtained from cBioPortal. The top 20 gene alterations in durable clinical benefit (DCB) were compared with those genes in no durable benefit (NDB). Survival analyses were performed using the Kaplan-Meier plot method and selected clinical variables to develop a novel nomogram.

RESULTS

The mutation of PTPRD was significantly related to progression free survival (PFS) and overall survival (OS) in advanced NSCLC with ICIs treatment (PFS: p = 0.0441, OS: p = 0.0086). The PTPRD mutation was closely related to tumor mutational burden (TMB) and tumor-infiltrating immune cells (TIICs). Two novel nomograms were built to predict the PFS and OS of advanced NSCLC patients with ICIs treatment.

CONCLUSIONS

Our study suggested that PTPRD mutations could serve as a predictive biomarker for the sensitivity to ICIs treatment and PFS and OS in advanced NSCLC with ICIs. Our systematic nomograms showed great potential value in clinical application to predict the PFS and OS for advanced NSCLC patients with ICIs.

摘要

背景

免疫检查点抑制剂（ICIs）已成为晚期非小细胞肺癌（NSCLC）的标准治疗方法。ICI 可为一些患者提供持久的反应并延长生存时间。随着下一代测序（NGS）在临床实践中的常规应用，整合预后因素建立新的列线图以提高 NSCLC 患者接受 ICI 治疗的临床预测能力至关重要。

方法

从 cBioPortal 获取接受 ICI 治疗的晚期 NSCLC 的临床信息、反应数据和基因组数据。将具有持久临床获益（DCB）的前 20 个基因改变与无持久获益（NDB）的基因进行比较。使用 Kaplan-Meier 绘图方法和选定的临床变量进行生存分析，以开发新的列线图。

结果

PTPRD 突变与晚期 NSCLC 患者接受 ICI 治疗后的无进展生存期（PFS）和总生存期（OS）显著相关（PFS：p = 0.0441，OS：p = 0.0086）。PTPRD 突变与肿瘤突变负担（TMB）和肿瘤浸润免疫细胞（TIICs）密切相关。建立了两个新的列线图来预测晚期 NSCLC 患者接受 ICI 治疗的 PFS 和 OS。

结论

我们的研究表明，PTPRD 突变可以作为预测对 ICI 治疗敏感性以及晚期 NSCLC 患者接受 ICI 治疗后的 PFS 和 OS 的生物标志物。我们的系统列线图在预测晚期 NSCLC 患者接受 ICI 治疗的 PFS 和 OS 方面具有很大的临床应用潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/2d67ad481687/aging-15-204964-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/b640c738c74c/aging-15-204964-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/314f364af8e4/aging-15-204964-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/b3cd3d347129/aging-15-204964-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/72eaa48e3ef3/aging-15-204964-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/2e5d9fdac898/aging-15-204964-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/2d67ad481687/aging-15-204964-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/b640c738c74c/aging-15-204964-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/314f364af8e4/aging-15-204964-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/b3cd3d347129/aging-15-204964-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/72eaa48e3ef3/aging-15-204964-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/2e5d9fdac898/aging-15-204964-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5246/10497019/2d67ad481687/aging-15-204964-g006.jpg

相似文献

1
PTPRD mutation is a prognostic biomarker for sensitivity to ICIs treatment in advanced non-small cell lung cancer.PTPRD 突变是晚期非小细胞肺癌对免疫检查点抑制剂治疗敏感性的预后生物标志物。
Aging (Albany NY). 2023 Aug 18;15(16):8204-8219. doi: 10.18632/aging.204964.
2
The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.ERBB4 突变在免疫检查点抑制剂治疗晚期非小细胞肺癌中的预后作用。
Mol Med. 2021 Oct 7;27(1):126. doi: 10.1186/s10020-021-00387-z.
3
Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.基于免疫相关基因 FGFR4 的列线图在免疫检查点抑制剂敏感的晚期非小细胞肺癌患者中的构建。
J Transl Med. 2021 Jan 6;19(1):22. doi: 10.1186/s12967-020-02679-0.
4
Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.鉴定和验证组织或 ctDNA PTPRD 磷酸酶结构域的有害突变作为非鳞状 NSCLC 免疫检查点抑制剂的预后和预测生物标志物。
BMC Med. 2021 Oct 7;19(1):239. doi: 10.1186/s12916-021-02075-5.
5
Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.基于靶向 NGS 检测的肿瘤突变负荷可预测非小细胞肺癌免疫检查点抑制剂的临床获益。
J Pathol. 2020 Jan;250(1):19-29. doi: 10.1002/path.5344. Epub 2019 Oct 24.
6
Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.ARID1 亚基可作为预测晚期非小细胞肺癌对免疫检查点抑制剂敏感性和预后的新型生物标志物。
Mol Med. 2020 Aug 13;26(1):78. doi: 10.1186/s10020-020-00208-9.
7
Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy.鉴定与对免疫治疗敏感的晚期非小细胞肺癌持久临床获益基因相关的列线图。
Heliyon. 2024 Mar 19;10(7):e27801. doi: 10.1016/j.heliyon.2024.e27801. eCollection 2024 Apr 15.
8
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合，以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
9
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
10
PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.PTPRD/PTPRT 突变作为多种癌症类型免疫检查点抑制剂的预测生物标志物。
Front Immunol. 2022 Sep 29;13:991091. doi: 10.3389/fimmu.2022.991091. eCollection 2022.

引用本文的文献

1
Potential biomarkers of primary resistance to first- and second-generation EGFR-TKIs in non-small-cell lung cancer: a real-world study.非小细胞肺癌对第一代和第二代表皮生长因子受体酪氨酸激酶抑制剂原发性耐药的潜在生物标志物：一项真实世界研究
Ther Adv Med Oncol. 2025 Apr 30;17:17588359251336632. doi: 10.1177/17588359251336632. eCollection 2025.
2
Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.ZFHX4突变对非小细胞肺癌和黑色素瘤中免疫检查点抑制剂疗效的预测价值。
Invest New Drugs. 2024 Dec;42(6):623-634. doi: 10.1007/s10637-024-01477-5. Epub 2024 Oct 5.
3

本文引用的文献

1
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.帕博利珠单抗联合化疗治疗鳞状非小细胞肺癌：III 期 KEYNOTE-407 研究的 5 年更新结果。
J Clin Oncol. 2023 Apr 10;41(11):1999-2006. doi: 10.1200/JCO.22.01990. Epub 2023 Feb 3.
2
PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.PTPRD/PTPRT 突变作为多种癌症类型免疫检查点抑制剂的预测生物标志物。
Front Immunol. 2022 Sep 29;13:991091. doi: 10.3389/fimmu.2022.991091. eCollection 2022.
3
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC.
[Exploring the Role of PCDHGB4 in the Occurrence of Lung Squamous Cell Carcinoma Based on Bioinformatics Analysis].
基于生物信息学分析探索原钙黏蛋白γB4在肺鳞状细胞癌发生中的作用
Zhongguo Fei Ai Za Zhi. 2024 Mar 20;27(3):199-215. doi: 10.3779/j.issn.1009-3419.2024.102.03.
4
Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy.鉴定与对免疫治疗敏感的晚期非小细胞肺癌持久临床获益基因相关的列线图。
Heliyon. 2024 Mar 19;10(7):e27801. doi: 10.1016/j.heliyon.2024.e27801. eCollection 2024 Apr 15.
非小细胞肺癌中同时发生的基因组改变与免疫治疗疗效
NPJ Precis Oncol. 2022 Jan 18;6(1):4. doi: 10.1038/s41698-021-00243-7.
4
The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.ERBB4 突变在免疫检查点抑制剂治疗晚期非小细胞肺癌中的预后作用。
Mol Med. 2021 Oct 7;27(1):126. doi: 10.1186/s10020-021-00387-z.
5
Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.鉴定和验证组织或 ctDNA PTPRD 磷酸酶结构域的有害突变作为非鳞状 NSCLC 免疫检查点抑制剂的预后和预测生物标志物。
BMC Med. 2021 Oct 7;19(1):239. doi: 10.1186/s12916-021-02075-5.
6
Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade.在透明细胞肾细胞癌中，嗜酸性特征与免疫检查点和血管生成阻断的治疗效果相关。
J Immunother Cancer. 2021 Sep;9(9). doi: 10.1136/jitc-2021-002922.
7
Association of Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades.免疫检查点阻断治疗的非小细胞肺癌患者中突变与更好临床结局的关联
Front Oncol. 2021 May 27;11:650122. doi: 10.3389/fonc.2021.650122. eCollection 2021.
8
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors.接受抗 PD-1/PD-L1 检查点抑制剂治疗的晚期或转移性尿路上皮癌患者的预处理嗜酸性粒细胞计数。
J Immunother. 2021 Sep 1;44(7):248-253. doi: 10.1097/CJI.0000000000000372.
9
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.人参多糖改变肠道微生物群和犬尿氨酸/色氨酸比值，增强抗程序性细胞死亡蛋白 1/程序性细胞死亡配体 1（抗 PD-1/PD-L1）免疫疗法的抗肿瘤作用。
Gut. 2022 Apr;71(4):734-745. doi: 10.1136/gutjnl-2020-321031. Epub 2021 May 18.
10
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.帕博利珠单抗对比化疗用于 PD-L1 肿瘤比例分数≥50%的转移性非小细胞肺癌的 5 年结果。
J Clin Oncol. 2021 Jul 20;39(21):2339-2349. doi: 10.1200/JCO.21.00174. Epub 2021 Apr 19.